The earnings call reflected strong performance and strategic growth, with raised guidance and strategic partnerships highlighting the positive trajectory. However, challenges such as ERP implementation issues and tariff headwinds were noted.

Company Guidance

During Solventum's Second Quarter 2025 Earnings Call, the company raised its sales growth and EPS guidance for the year due to consistent positive momentum and strong execution. They reported a 2.8% increase in organic sales growth, with total sales reaching $2.2 billion, and noted a 3.9% increase on a reported basis, including a 110 basis point benefit from foreign exchange. The MedSurg segment led with a 3.9% organic growth, supported by a commercial restructuring and new product launches. The company also highlighted a 3.2% organic growth in the Health Information Systems segment. Gross margins improved by 20 basis points over the prior year, reaching 56% of sales. Solventum revised its 2025 EPS guidance to a range of $5.80 to $5.95, up from $5.45 to $5.65, reflecting the strong quarterly performance and favorable adjustments in tariff and tax expectations. Despite these upward revisions, the company maintained its free cash flow guidance at $450 million to $550 million.

Raised Sales Growth and EPS Guidance

Solventum announced raising their sales growth and EPS guidance for the year, indicating positive momentum and strong execution.

Strategic Focus on Growth Drivers

The company identified five growth drivers accounting for over 80% of future growth, including negative pressure wound therapy and IV site management.

Strong MedSurg Performance

The MedSurg segment delivered $1.2 billion in sales, an increase of 3.9% on an organic basis, driven by Infection Prevention and Surgical Solutions.

Partnership with Ensemble

Announced a new partnership with Ensemble, a leader in revenue cycle management services, to enhance their autonomous coding solutions.

Recognition and Awards

Solventum was placed on the Fortune 500 and named a best company to work for by U.S. News & World Report.

Solventum Corporation (SOLV) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SOLV Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	1.42 / -	1.64	―	―	―
Aug 07, 2025	2025 (Q2)	1.45 / 1.69	1.56	8.33% (+0.13)
May 08, 2025	2025 (Q1)	1.21 / 1.34	2.08	-35.58% (-0.74)
Feb 27, 2025	2024 (Q4)	1.31 / 1.41	2.311	-38.99% (-0.90)
Nov 07, 2024	2024 (Q3)	1.39 / 1.64	2.664	-38.44% (-1.02)
Aug 08, 2024	2024 (Q2)	1.50 / 1.56	1.859	-16.08% (-0.30)	―
May 09, 2024	2024 (Q1)	1.75 / 2.08	1.696	22.64% (+0.38)		―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SOLV Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$71.95	$73.39	+2.00%
May 08, 2025	$66.63	$70.23	+5.40%
Feb 27, 2025	$83.44	$79.75	-4.42%
Nov 07, 2024	$75.07	$72.43	-3.52%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.